Leading independent proxy advisory firm iss recommends seelos stockholders vote "for" all proxy proposals at the special meeting to be held on january 10, 2024

New york, jan. 2, 2024 /prnewswire/ -- seelos therapeutics, inc. (nasdaq: seel) ("seelos"), a clinical-stage biopharmaceutical company focused on the development of therapies for central nervous system disorders and rare diseases, today announced that institutional shareholder services ("iss"), a leading independent proxy voting and corporate governance advisory firm, recommends seelos stockholders vote "for" all proposals at the special meeting of stockholders, including management's proposal to increase the number of authorized shares of common stock.  the special meeting is scheduled to be held virtually, via live webcast at www.virtualshareholdermeeting.com/seel2024sm, on wednesday, january 10, 2024 at 8:00 a.m.
SEEL Ratings Summary
SEEL Quant Ranking